Apellis Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Basic from 2020 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Apellis Pharmaceuticals, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from 2020 to Q3 2025.
  • Apellis Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2025 was 126M shares, a 1.76% increase year-over-year.
  • Apellis Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 124M shares, a 4.4% increase from 2023.
  • Apellis Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 119M shares, a 11.8% increase from 2022.
  • Apellis Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 106M shares, a 25.7% increase from 2021.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Growth (%)

Apellis Pharmaceuticals, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 126M +2.19M +1.76% Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-30
Q2 2025 126M +2.12M +1.71% Apr 1, 2025 Jun 30, 2025 10-Q 2025-07-31
Q1 2025 125M +2.5M +2.03% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 124M +5.23M +4.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-28
Q3 2024 124M +3.94M +3.28% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-30
Q2 2024 124M +4.59M +3.85% Apr 1, 2024 Jun 30, 2024 10-Q 2025-07-31
Q1 2024 123M +9.08M +7.98% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 119M +12.6M +11.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-28
Q3 2023 120M +11.2M +10.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 119M +12.7M +11.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 114M +15.8M +16.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 106M Oct 1, 2022 Dec 31, 2022 10-K 2025-02-28
Q3 2022 109M +109M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 107M +107M Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-31
Q1 2022 98.1M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q3 2021 85.7K* Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 80.7K* Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08

Apellis Pharmaceuticals, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 124M +5.23M +4.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-28
2023 119M +12.6M +11.8% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-28
2022 106M +21.7M +25.7% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-28
2021 84.4M +9.26M +12.3% Jan 1, 2021 Dec 31, 2021 10-K/A 2024-02-29
2020 75.2M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.